Eckert & Ziegler BEBIG

Changes to the Board of Directors. Capital increase by contribution in cash

Press Release

REGULATED INFORMATION

Eckert & Ziegler BEBIG: Changes to the Board of Directors - Prof. Dr. Lutz Uharek and Dr. Harald Hasselmann elected as new Board of Directors members. Capital increase by contribution in cash with cancellation of the preferential rights of the current shareholders, authorized capital  and reverse stock split

Seneffe, June 9, 2016. Eckert & Ziegler BEBIG SA has two new Board of Directors members. Prof. Dr. Lutz Uharek was elected to be a new member of the Board of Directors at today's Annual General Meeting in Seneffe (Belgium). The physician follows Martin Hölscher, whose time in office has ended after two terms in accordance with the Articles of Association. "We would like to thank Mr. Hölscher for the excellent and trustful working relationship and are pleased to have found in Professor Uharek a qualified successor with comprehensive medical expertise," said Dr. Andreas Eckert, Chairman of the Board of Directors of Eckert & Ziegler BEBIG SA

Prof. Uharek is a hematology oncologist and a chief resident at the Medical Department, Division of Hematology, Oncology and Tumor Immunology at the Charité Campus Virchow Klinikum in Berlin. As an expert in the field of stem cell transplantation and clinical cell therapy, and as the head of scientific working groups and a principal investigator in phase I and II studies, he has extensive expertise in translational research and the early clinical use of cellular immunotherapeutics.

The Annual General Meeting also elected Dr. Harald Hasselman, who has been with the company since October 2015, to the Board of Directors. He follows Dr. Edgar Löffler, who remains a Managing Director, but is leaving the Board of Directors at his own request. "Over the past eight years, Dr. Löffler has played an instrumental role in driving the focus toward being a complete provider of brachytherapy. We would like to thank him for this, and we are pleased that he will continue to support the company on its growth course in his role as member of the management committee," said Dr. Andreas Eckert, Chairman of the Board of Directors of Eckert & Ziegler BEBIG SA.

An Extraordinary General Meeting, that followed the Annual General Meeting, decided to increase its capital by way of a contribution in cash with cancellation of the preferential right of the current shareholders for an amount of EUR 5,056,168.48, of which EUR 3,560,771.10 EUR is allocated to the share capital and EUR 1,495,397.38 as share premium. The beneficiary of the cancellation of the preferential rights is the company under German law, Eckert & Ziegler EZAG AG, i.e. the controlling shareholder of the company.